Criterios Farmacoeconómicos Usados en México para la Evaluación de Tratamientos en Personas en Fases Terminales.

Autor: Rizo Ríos P; Director General Adjunto de Priorización Consejo de Salubridad General México D.F, México. Electronic address: pedro.rizo@salud.gob.mx., González Rivera A; Director General Adjunto de Priorización Consejo de Salubridad General México D.F, México., Campos Ramírez O; Director General Adjunto de Priorización Consejo de Salubridad General México D.F, México., Lifshitz Guinzberg A; Director General Adjunto de Priorización Consejo de Salubridad General México D.F, México.
Jazyk: angličtina
Zdroj: Value in health regional issues [Value Health Reg Issues] 2012 Dec; Vol. 1 (2), pp. 264-266. Date of Electronic Publication: 2012 Dec 12.
DOI: 10.1016/j.vhri.2012.10.004
Abstrakt: In Mexico, the primary aim of "Healthcare Supplies Catalog" (CBCISS) is guide the optimization of public resources to the attention of the health problems of the country, through the use of medicines, treatments, procedures and devices which have proven safety, efficacy and efficiency. Since May 2003, the Commission of CBCISS established as a requirement for updating submits a Health Economic Evaluation (EE) of the product. Therefore, in 2008, was a prepared and published methodological guideline for the conduct of studies of economic value (GCEEE). In 2011 was developed some strategies as updated the Internal Regulations and developed the Evaluation Guide Health Products (GEIS); both complement the GCEEE and oriented between other things, to increased the availability of technologies in different public institutions, decreased likelihood to commit injustices and inequities in access to supplies and standardize a transparent process. With the epidemiological transition, the cares of patients with chronic or terminal phase are contributing to the escalating costs of health care. The escalating costs are driven by the use of therapies that unfortunately have only marginal benefits, increasing the health and social costs, and upholding financial sustainability of healthcare systems. Therefore the stakeholders must decide the order of preference and establish an allocation methodology.
(Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: